Statement: There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 3/6 (50.00%)   Febrile neutropenia 0/6 (0.00%)   Leukopenia 0/6 (0.00%)   Neutropenia 0/6 (0.00%)   Thrombocytopenia 0/6 (0.00%)   Cardio-respiratory arrest 0/6 (0.00%)   Cardiopulmonary failure 0/6 (0.00%)   Vertigo 0/6 (0.00%)   Visual impairment 0/6 (0.00%)   Abdominal pain 0/6 (0.00%)   Diarrhoea 0/6 (0.00%)   Dysphagia 0/6 (0.00%)   Gastric ulcer 0/6 (0.00%) Adverse Events 2:   Total: 6/17 (35.29%)   Febrile neutropenia 0/17 (0.00%)   Leukopenia 0/17 (0.00%)   Neutropenia 0/17 (0.00%)   Thrombocytopenia 0/17 (0.00%)   Cardio-respiratory arrest 1/17 (5.88%)   Cardiopulmonary failure 0/17 (0.00%)   Vertigo 0/17 (0.00%)   Visual impairment 0/17 (0.00%)   Abdominal pain 0/17 (0.00%)   Diarrhoea 1/17 (5.88%)   Dysphagia 0/17 (0.00%)   Gastric ulcer 1/17 (5.88%)